Trials / Sponsors / PYC Therapeutics
PYC Therapeutics
Industry · 8 registered clinical trials — 3 currently recruiting.
| Status | Trial | Phase | Started |
|---|---|---|---|
| Recruiting | Safety of Single and Repeat Dose of PYC-001 Eye Injections in People With Autosomal Dominant Optic Atrophy (My OPA1 Gene Mutation, Autosomal Dominant Optic Atrophy, Hereditary Optic Atrophies | Phase 1 / Phase 2 | 2025-09-30 |
| Recruiting | A Repeat-Dose, Open-Label, Two Arm Safety and Efficacy Study of Two Doses of VP-001 Administered Intravitreall Retinitis Pigmentosa 11, Retinal Degeneration, Retinal Disease | Phase 1 / Phase 2 | 2025-06-01 |
| Recruiting | Phase 1 Study to Evaluate the Safety and Tolerability of Intravenously Administered PYC-003 Autosomal Dominant Polycystic Kidney Disease (ADPKD) | Phase 1 | 2025-04-07 |
| Active Not Recruiting | SAD of IVT PYC-001 in OPA1 Mutation-Associated Autosomal Dominant Optic Atrophy (Sundew) OPA1 Gene Mutation, Autosomal Dominant Optic Atrophy, Hereditary Optic Atrophies | Phase 1 | 2024-10-31 |
| Completed | MAD of IVT VP-001 in PRPF31 Mutation-Associated Retinal Dystrophy Subjects (Wallaby) Retinitis Pigmentosa 11, Retinal Degeneration, Eye Diseases | Phase 1 | 2024-06-13 |
| Terminated | Natural History of Autosomal Dominant Optic Atrophy (ADOA), Caused by OPA1 Mutation Autosomal Dominant Optic Atrophy, Optic Atrophy, Autosomal Dominant, Optic Atrophies, Hereditary | — | 2024-02-28 |
| Completed | SAD of IVT VP-001 in PRPF31 Mutation-Associated Retinal Dystrophy Subjects Retinal Dystrophy, PRPF31 Mutationassociated Retinal Dystrophy, RP11 | Phase 1 | 2023-04-20 |
| Active Not Recruiting | Natural History of PRPF31 Mutation-Associated Retinal Dystrophy Retinitis Pigmentosa, Eye Diseases, Hereditary, Retinal Dystrophies | — | 2022-07-07 |